Ambar Protein [AMBARPIL] vs Britannia Industries [BRITANNIA] Detailed Stock Comparison
Ambar Protein
BSE
Loading...
Britannia Industries
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Ambar Protein wins in 7 metrics, Britannia Industries wins in 5 metrics, with 0 ties. Ambar Protein appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Ambar Protein | Britannia Industries | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | 60.78 | N/A |
| Price-to-Book Ratio | 4.02 | 30.67 | Ambar Protein |
| Debt-to-Equity Ratio | 74.75 | 28.45 | Britannia Industries |
| PEG Ratio | N/A | 20.25 | N/A |
| EV/EBITDA | 10.64 | 42.06 | Ambar Protein |
| Profit Margin (TTM) | 1.95% | 12.02% | Britannia Industries |
| Operating Margin (TTM) | 1.71% | 14.60% | Britannia Industries |
| EBITDA Margin (TTM) | 1.71% | 14.60% | Britannia Industries |
| Return on Equity | N/A | 49.73% | N/A |
| Return on Assets (TTM) | N/A | 24.65% | N/A |
| Free Cash Flow (TTM) | N/A | $21.06B | N/A |
| Dividend Yield | N/A | 2.57% | N/A |
| 1-Year Return | 66.81% | -4.27% | Ambar Protein |
| Price-to-Sales Ratio (TTM) | 0.31 | 7.32 | Ambar Protein |
| Enterprise Value | $1.68B | $1,336.01B | Britannia Industries |
| EV/Revenue Ratio | 0.38 | 7.32 | Ambar Protein |
| Gross Profit Margin (TTM) | N/A | 39.16% | N/A |
| Revenue per Share (TTM) | $776 | $758 | Ambar Protein |
| Earnings per Share (Diluted) | N/A | $91.24 | N/A |
| Beta (Stock Volatility) | -2.16 | 0.53 | Ambar Protein |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Ambar Protein vs Britannia Industries Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ambar Protein | -1.99% | -6.87% | -32.52% | 12.44% | 24.14% | 25.12% |
| Britannia Industries | -0.93% | 1.96% | -2.86% | 1.99% | 15.43% | 15.66% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ambar Protein | 66.81% | -15.61% | 1,508.77% | 1,508.77% | 1,508.77% | 1,508.77% |
| Britannia Industries | -4.27% | 51.93% | 46.17% | 272.96% | 2,665.01% | 4,834.60% |
Performance & Financial Health Analysis: Ambar Protein vs Britannia Industries
| Metric | AMBARPIL | BRITANNIA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.40B | ₹1.34T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 347 | 373,627 |
| 90 Day Avg. Volume | 554 | 333,853 |
| Last Close | ₹244.05 | ₹5,545.50 |
| 52 Week Range | ₹144.40 - ₹432.85 | ₹4,506.00 - ₹6,469.90 |
| % from 52W High | -43.62% | -14.29% |
| All-Time High | ₹843.50 (Sep 26, 2022) | ₹6,469.90 (Sep 30, 2024) |
| % from All-Time High | -71.07% | -14.29% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.26% | 0.09% |
| Quarterly Earnings Growth | -0.57% | 0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.12% |
| Operating Margin (TTM) | 0.02% | 0.15% |
| Return on Equity (TTM) | N/A | 0.50% |
| Debt to Equity (MRQ) | 74.75 | 28.45 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹60.65 | ₹180.83 |
| Cash per Share (MRQ) | ₹2.10 | ₹51.66 |
| Operating Cash Flow (TTM) | ₹0 | ₹27.29B |
| Levered Free Cash Flow (TTM) | ₹0 | ₹21.79B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 2.57% |
| Last 12-Month Dividend | N/A | ₹148.50 |
Valuation & Enterprise Metrics Analysis: Ambar Protein vs Britannia Industries
| Metric | AMBARPIL | BRITANNIA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 60.78 |
| Forward P/E | N/A | 68.15 |
| PEG Ratio | N/A | 20.25 |
| Price to Sales (TTM) | 0.31 | 7.32 |
| Price to Book (MRQ) | 4.02 | 30.67 |
| Market Capitalization | ||
| Market Capitalization | ₹1.40B | ₹1.34T |
| Enterprise Value | ₹1.68B | ₹1.34T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.38 | 7.32 |
| Enterprise to EBITDA | 10.64 | 42.06 |
| Risk & Other Metrics | ||
| Beta | -2.16 | 0.53 |
| Book Value per Share (MRQ) | ₹60.65 | ₹180.83 |
Financial Statements Comparison: Ambar Protein vs Britannia Industries
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AMBARPIL | BRITANNIA |
|---|---|---|
| Revenue/Sales | N/A | ₹45.35B |
| Cost of Goods Sold | N/A | ₹27.59B |
| Gross Profit | N/A | ₹17.76B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | N/A | ₹6.75B |
| EBITDA | N/A | ₹8.09B |
| Pre-Tax Income | N/A | ₹7.01B |
| Income Tax | N/A | ₹1.81B |
| Net Income (Profit) | N/A | ₹5.20B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AMBARPIL | BRITANNIA |
|---|---|---|
| Cash & Equivalents | N/A | ₹1.33B |
| Total Current Assets | N/A | ₹39.14B |
| Total Current Liabilities | N/A | ₹36.18B |
| Long-Term Debt | N/A | ₹7.32B |
| Total Shareholders Equity | N/A | ₹43.81B |
| Retained Earnings | N/A | ₹40.36B |
| Property, Plant & Equipment | N/A | ₹27.35B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AMBARPIL | BRITANNIA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AMBARPIL | BRITANNIA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 347 | 373,627 |
| Average Daily Volume (90 Day) | 554 | 333,853 |
| Shares Outstanding | 5.75M | 240.87M |
| Float Shares | 953,370 | 117.62M |
| % Held by Insiders | 0.79% | 0.51% |
| % Held by Institutions | 0.00% | 0.26% |
Dividend Analysis & Yield Comparison: Ambar Protein vs Britannia Industries
| Metric | AMBARPIL | BRITANNIA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹148.50 |
| Last 12-Month Dividend Yield | N/A | 2.57% |
| 3-Year Avg Annual Dividend | N/A | ₹73.50 |
| 3-Year Avg Dividend Yield | N/A | 1.42% |
| 3-Year Total Dividends | N/A | ₹220.50 |
| Ex-Dividend Date | N/A | Aug 04, 2025 |